| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 1g | |||
| Other Sizes |
Sitaxsentan (IPI 1040; TBC-11251) is a novel and potent endothelin A receptor (ETA) antagonist is an orally bioavailable endothelin A receptor (ETA) antagonist with anti-hypertensive activity. It inhibits ETA with IC50 and Ki of 1.4 nM and 0.43 nM, respectively. Sitaxentanis an approved medication for the treatment of pulmonary arterial hypertension (PAH).
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
70-100% Kidneys (50% to 60%) Feces (40% to 50%) Metabolism/Metabolites Liver (CYP2C9 and CYP3A4 mediated) Biological Half-Life 10 hours |
||
| Toxicity/Toxicokinetics |
Protein Binding
99%+ |
||
| References | |||
| Additional Infomation |
Sitaxentan belongs to the benzodioxane class of drugs. It was previously marketed under the brand name Thelin by Encysive Pharmaceuticals for the treatment of pulmonary arterial hypertension (PAH) until Pfizer acquired Encysive in February 2008. In 2010, Pfizer withdrew Sitaxentan from the market due to concerns about its hepatotoxicity. Drug Indications It has been studied for the treatment of pulmonary arterial hypertension, connective tissue diseases, hypertension, and congestive heart failure. Mechanism of Action Sitaxentan is a competitive antagonist of endothelin-1 at both endothelin A (ET-A) and endothelin B (ET-B) receptors. Normally, the binding of endothelin-1 to either ET-A or ET-B receptors leads to pulmonary vasoconstriction. Sitaxentan reduces pulmonary vascular resistance by blocking this interaction. Sitaxentan has a higher affinity for endothelin A (ET-A) than for endothelin B (ET-B).
Pharmacodynamics Sitasentan belongs to the class of endothelin receptor antagonists (ERAs). Patients with pulmonary arterial hypertension (PAH) have elevated levels of endothelin (a potent vasoconstrictor) in their plasma and lung tissue. Sitasentan blocks the binding of endothelin to its receptors, thereby eliminating the harmful effects of endothelin. |
| Molecular Formula |
C₁₈H₁₅CLN₂O₆S₂
|
|---|---|
| Molecular Weight |
454.90
|
| Exact Mass |
454.006
|
| CAS # |
184036-34-8
|
| Related CAS # |
Sitaxsentan sodium;210421-74-2
|
| PubChem CID |
216235
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6g/cm3
|
| Boiling Point |
600.4ºC at 760 mmHg
|
| Flash Point |
316.9ºC
|
| Vapour Pressure |
2.25E-14mmHg at 25°C
|
| Index of Refraction |
1.687
|
| LogP |
5.115
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
720
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(C1=C(C(CC2=CC3=C(C=C2C)OCO3)=O)SC=C1)(NC4=C(C(C)=NO4)Cl)=O
|
| InChi Key |
PHWXUGHIIBDVKD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,21H,6,8H2,1-2H3
|
| Chemical Name |
N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
|
| Synonyms |
IPI-1040Thelin Sitaxentan sodiumIPI-1040 TBC11251IPI1040TBC-11251 IPI 1040TBC 11251 TBC-11251 sodium salt, Sitaxsentan
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1983 mL | 10.9914 mL | 21.9829 mL | |
| 5 mM | 0.4397 mL | 2.1983 mL | 4.3966 mL | |
| 10 mM | 0.2198 mL | 1.0991 mL | 2.1983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
